These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 23920144)
1. Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Xue Q; Zhou Y; Wan C; Lv L; Chen B; Cao X; Ju G; Huang Y; Ni R; Mao G Exp Mol Pathol; 2013 Dec; 95(3):313-8. PubMed ID: 23920144 [TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Zhang Y; Miao Y; Yi J; Wang R; Chen L Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829 [TBL] [Abstract][Full Text] [Related]
3. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Fumoto S; Hiyama K; Tanimoto K; Noguchi T; Hihara J; Hiyama E; Noguchi T; Nishiyama M Cancer Lett; 2009 Feb; 274(1):25-32. PubMed ID: 18823699 [TBL] [Abstract][Full Text] [Related]
4. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features. Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572 [TBL] [Abstract][Full Text] [Related]
6. The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer. Chen JT; Cheng YW; Chou MC; Sen-Lin T; Lai WW; Ho WL; Lee H Clin Cancer Res; 2003 Sep; 9(11):4200-4. PubMed ID: 14519646 [TBL] [Abstract][Full Text] [Related]
7. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100 [TBL] [Abstract][Full Text] [Related]
8. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821 [TBL] [Abstract][Full Text] [Related]
9. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232 [TBL] [Abstract][Full Text] [Related]
10. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Alaminos M; Dávalos V; Ropero S; Setién F; Paz MF; Herranz M; Fraga MF; Mora J; Cheung NK; Gerald WL; Esteller M Cancer Res; 2005 Apr; 65(7):2565-71. PubMed ID: 15805250 [TBL] [Abstract][Full Text] [Related]
11. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585 [TBL] [Abstract][Full Text] [Related]
12. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194 [TBL] [Abstract][Full Text] [Related]
13. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Hayashi M; Tokuchi Y; Hashimoto T; Hayashi S; Nishida K; Ishikawa Y; Nakagawa K; Tsuchiya S; Okumura S; Tsuchiya E Anticancer Res; 2001; 21(1B):535-40. PubMed ID: 11299800 [TBL] [Abstract][Full Text] [Related]
14. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389 [TBL] [Abstract][Full Text] [Related]
15. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677 [TBL] [Abstract][Full Text] [Related]
16. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC. Grimminger PP; Maus MK; Schneider PM; Metzger R; Hölscher AH; Sugita H; Danenberg PV; Alakus H; Brabender J Lung Cancer; 2012 Oct; 78(1):87-91. PubMed ID: 22884253 [TBL] [Abstract][Full Text] [Related]
17. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575 [TBL] [Abstract][Full Text] [Related]
18. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC. Pesta M; Kulda V; Topolcan O; Safranek J; Vrzalova J; Cerny R; Holubec L Anticancer Res; 2009 Nov; 29(11):4535-9. PubMed ID: 20032402 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205 [TBL] [Abstract][Full Text] [Related]